Development grant
Cobra Biomanufacturing plc has been awarded a £1.1 million grant from the UK Department of Trade and Industry to evaluate the use of its ORT-VAC technology in oral vaccines against bird flu and HIV/AIDS. The company will work in collaboration with researchers from Cambridge University and the Royal Holloway, London.
Cobra’s proprietary ORT-VAC system uses harmless bacteria to deliver vaccines orally. The technology has been proven in oral vaccines against anthrax and plague developed in conjunction with the UK Defence Science and Technology Laboratory.
Receive the Funding Newswire each Tuesday, our Policy Bulletin each Thursday, and news about bridging Europe’s east-west innovation gap twice a month in The Widening. 
A unique international forum for public research organisations and companies to connect their external engagement with strategic interests around their R&D system.
